Restructure Information
On March 15, 2021, Purdue Pharma L.P. submitted a Plan of Reorganization to the Bankruptcy Court. The Plan charts a path for more than $10 billion of value, including 100% of Purdue’s assets and millions of doses of opioid addiction treatment and overdose reversal medicines, to be delivered to claimants and communities across the country affected by the opioid crisis.

READ MORE HERE >

Our Commitment to Safety as we Navigate Coronavirus

We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.

Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.

Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. We continue to progress our public health initiatives and our pipeline. Please continue to contact us through your normal channels.  Our medical team is available and if you have questions related to our products please contact us; 1-888-827-0618; Ask Adlon Medical. Other contact information can be found here.

We are particularly concerned that the pandemic is triggering indirect health risks for people with (or those at risk of experiencing) substance use disorders. Through our office of Corporate Social Responsibility, Purdue is providing $500,000 in additional monetary support to local and national organizations focused on the pandemic, as well as those delivering harm reduction programs, improving access to medication-assisted treatment, and supporting continuity of recovery services during the pandemic.

We are confident that, by facing new challenges through a data-driven, health-conscious, and business continuity-focused lens, we can continue to serve those who rely on our medicines and products.

Adlon Therapeutics logo

Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., is a specialty pharmaceutical company committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). Our mission is to serve patients and the ADHD community by developing innovative medicines and supporting responsible prescription stimulant utilization through awareness, research, and supporting policies that align with the appropriate diagnosis and treatment of ADHD. For more information, please visit www.adlontherapeutics.com or follow us on Twitter and LinkedIn.

Prescribing Responsibly

Ask Adlon Medical

Adhansia XR®

(Methylphenidate Hydrochloride) Extended-Release Capsules CII

Warning: Abuse and Dependence
CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

Bitnami